Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Download

Total Articles

4
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (0)

Searched Name

Truxima

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Type

Show more Refine

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

First Author Affiliations

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Corresponding Author Affiliations

Show more Refine

Category

Show more Refine

Number	Citation Analysis
1	Ublituximab (Briumvi) for relapsing multiple sclerosis. Med Lett Drugs Ther 2023;65:36-8. [PMID: 36877282 DOI: 10.58347/tml.2023.1671c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [Subscribe] [Scholar Register] [Indexed: 03/07/2023] Abstract Collapse Key Words Aubagio Briumvi Copaxone Gilenya Kesimpta Mavenclad Mayzent Ocrevus Rebif Riabni Rituxan Ruxience Tecfidera Truxima Tysabri Zeposia adverse effects cladribine dimethyl fumarate dosage drug interactions efficacy fingolimod glatiramer acetate interferon beta lactation multiple sclerosis natalizumab ocrelizumab ofatumumab ozanimod pregnancy rituximab safety siponimod teriflunomide ublituximab Collapse MESH Headings Collapse Grants Collapse Affiliation(s) Collapse
2	Expanded Table: Some biologic drugs and JAK inhibitors for rheumatoid arthritis. Med Lett Drugs Ther 2021;63:e187-9. [PMID: 35085212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023] Abstract Collapse Key Words Actemra Amgevita Avsola Brenzys Cimzia Enbrel Erelzi Hadlima Hulio Humira Hyrimoz Idacio Inflectra Kevzara Olumiant Orencia Remicade Remsima Renflexis Riabni Rinvoq Rituxan Riximyo Ruxience Simponi TNF inhibitors Truxima Xeljanz abatacept adalimumab adverse effects baricitinib certolizumab dosage etanercept golimumab infliximab lactation pregnancy rheumatoid arthritis rituximab safety sarilumab tocilizumab tofacitinib upadacitinib Collapse MESH Headings Antirheumatic Agents/adverse effects Antirheumatic Agents/therapeutic use Arthritis, Rheumatoid/diagnosis Arthritis, Rheumatoid/drug therapy Arthritis, Rheumatoid/immunology Biological Factors/adverse effects Biological Factors/therapeutic use Clinical Decision-Making Decision Support Techniques Drug Therapy, Combination Humans Janus Kinase Inhibitors/adverse effects Janus Kinase Inhibitors/therapeutic use Patient Selection Predictive Value of Tests Severity of Illness Index Treatment Outcome Collapse Grants Collapse Affiliation(s) Collapse
3	Drugs for rheumatoid arthritis. Med Lett Drugs Ther 2021;63:177-84. [PMID: 35085210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023] Abstract Collapse Key Words Actemra Arava Aristospan Avsola COVID-19 Celebrex Cimzia Comirnaty DMARDs Depo-Medrol Enbrel Humira Inflectra JAK inhibitors Kevzara NSAIDs Olumiant Orencia Otrexup PennSaid Plaquenil Questran Rasuvo Reditrex Remicade Renflexis Riabni Rinvoq Rituxan Ruxience Simponi Spikevax TNF inhibitors Trexall Truxima Voltaren Xatmep Xeljanz abatacept adalimumab adverse effects baricitinib biologic celecoxib certolizumab corticosteroids diclofenac drug interactions etanercept golimumab hydroxychloroquine infliximab lactation leflunomide methotrexate methylprednisolone prednisone pregnancy rheumatoid arthritis rituximab safety sarilumab sulfasalazine tocilizumab tofacitinib triamcinolone upadacitinib vaccines Collapse MESH Headings Antirheumatic Agents/therapeutic use Arthritis, Rheumatoid/drug therapy Humans COVID-19 Drug Treatment Collapse Grants Collapse Affiliation(s) Collapse
4	Drugs for multiple sclerosis. Med Lett Drugs Ther 2021;63:42-8. [PMID: 33976089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023] Abstract Collapse Key Words Aubagio Avonex Betaseron Copaxone Extavia Gilenya Glatect Glatopa Kesimpta Lemtrada Mavenclad Mayzent Orevus Plegridy Rebif Riabni Rituxan Riximyo Ruxience Tecfidera Truxima Tysabri Vumerity Zeposia adverse effects alemtuzumab cladribine dimethyl fumarate diroximel dosage drug interactions efficacy fingolimod glatiramer acetate interferon beta lactation mitoxantrone multiple sclerosis natalizumab ocrelizumab ofatumumab ozanimod pregnancy rituximab safety siponimod teriflunomide Collapse MESH Headings Drug Administration Routes Drug Interactions Humans Immunologic Factors/administration & dosage Immunologic Factors/adverse effects Immunologic Factors/therapeutic use Immunosuppressive Agents/administration & dosage Immunosuppressive Agents/adverse effects Immunosuppressive Agents/therapeutic use Multiple Sclerosis/drug therapy Multiple Sclerosis, Relapsing-Remitting/drug therapy Collapse Grants Collapse Affiliation(s) Collapse